CD8+Trm (CD103+CD49a+CD69+PD-1+CD39+)cells demonstrate enhanced proliferation and cytotoxicity toward autologous cancer cells.Higher density of CD8+Trm in immunotherapy-naive tumors is associated with improved outcomes and Trm density increases during immunotherapy in responders. This evidence concerns the gene CD8A and cancer.